127 related articles for article (PubMed ID: 29162464)
1. Biochemical and Biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5.
Raghav D; Sebastian J; Rathinasamy K
Int J Biol Macromol; 2018 Apr; 109():1189-1208. PubMed ID: 29162464
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
3. Monastrol inhibition of the mitotic kinesin Eg5.
Cochran JC; Gatial JE; Kapoor TM; Gilbert SP
J Biol Chem; 2005 Apr; 280(13):12658-67. PubMed ID: 15665380
[TBL] [Abstract][Full Text] [Related]
4. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
6. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
7. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
8. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
9. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.
Skoufias DA; DeBonis S; Saoudi Y; Lebeau L; Crevel I; Cross R; Wade RH; Hackney D; Kozielski F
J Biol Chem; 2006 Jun; 281(26):17559-69. PubMed ID: 16507573
[TBL] [Abstract][Full Text] [Related]
10. A structural model for monastrol inhibition of dimeric kinesin Eg5.
Krzysiak TC; Wendt T; Sproul LR; Tittmann P; Gross H; Gilbert SP; Hoenger A
EMBO J; 2006 May; 25(10):2263-73. PubMed ID: 16642039
[TBL] [Abstract][Full Text] [Related]
11. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
12. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
13. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
[TBL] [Abstract][Full Text] [Related]
15. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells.
Banerjee M; Singh P; Panda D
FEBS J; 2010 Aug; 277(16):3437-48. PubMed ID: 20646066
[TBL] [Abstract][Full Text] [Related]
16. Morelloflavone as a novel inhibitor of mitotic kinesin Eg5.
Ogunwa TH; Taii K; Sadakane K; Kawata Y; Maruta S; Miyanishi T
J Biochem; 2019 Aug; 166(2):129-137. PubMed ID: 30785183
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
18. MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5.
Sebastian J; Raghav D; Rathinasamy K
Mol Divers; 2023 Jun; 27(3):1203-1221. PubMed ID: 35789974
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
20. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]